article

1. Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients..  bioRxiv : the preprint server for biology.  2023
2. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial..  Open forum infectious diseases.  10:-. 2023
3. Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer..  AIDS (London, England).  37:2049-2057. 2023
4. A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection..  Microbiology spectrum.  11:-. 2023
5. Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials..  Clinical and translational science.  16:524-535. 2023
6. Dasatinib: effects on the macrophage phospho proteome with a focus on SAMHD1 and HIV-1 infection..  Clinical research in HIV/AIDS.  8. 2022
7. Cytokine Deficiencies in Patients with Long-COVID..  Journal of clinical & cellular immunology.  13. 2022
8. Host Cell Redox Alterations Promote Latent HIV-1 Reactivation through Atypical Transcription Factor Cooperativity..  Viruses.  14. 2022
9. Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID..  medRxiv : the preprint server for health sciences.  2022
10. A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation..  Scientific reports.  11:-. 2021
11. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation..  Biochemical pharmacology.  -. 2021
12. Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence..  Biochemical pharmacology.  -. 2021
13. A Rapid and Affordable Point-of-care Test for Detection of SARS-Cov-2-Specific Antibodies Based on Hemagglutination and Artificial Intelligence-Based Image Interpretation..  Research square.  2021
14. Euphorbia usambarica.  Pharmaceuticals (Basel, Switzerland).  14. 2021
15. Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS..  Frontiers in immunology.  -. 2021
16. Diverse Mucosal-Associated Invariant TCR Usage in HIV Infection..  ImmunoHorizons.  5:360-369. 2021
17. Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis..  Open forum infectious diseases.  8:-. 2021
18. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions..  Virology journal.  18:-. 2021
19. Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV..  International journal of molecular sciences.  21. 2020
20. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19..  Blood advances.  4:4864-4868. 2020
21. Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions..  bioRxiv : the preprint server for biology.  2020
22. Recommendations for measuring HIV reservoir size in cure-directed clinical trials..  Nature medicine.  26:1339-1350. 2020
23. Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents..  Antimicrobial agents and chemotherapy.  64. 2020
24. In Vivo.  Cell reports. Medicine.  1:-. 2020
25. Senotherapeutics and HIV-1 Persistence..  Current HIV/AIDS reports.  17:219-225. 2020
26. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019..  Fertility and sterility.  113:1135-1139. 2020
27. Senotherapeutics for HIV and aging..  Current opinion in HIV and AIDS.  15:83-93. 2020
28. Down but not out..  eLife.  2019
29. Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV..  Current HIV/AIDS reports.  16:414-422. 2019
30. Paenibacillus.  Oxford medical case reports.  2019:-. 2019
31. Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages..  The Journal of infectious diseases.  219:777-785. 2019
32. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation..  Nature communications.  9:-. 2018
33. Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal..  Antimicrobial agents and chemotherapy.  62. 2018
34. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents..  JCI insight.  3. 2018
35. Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus..  AIDS research and human retroviruses.  34:769-777. 2018
36. SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition..  mBio.  9. 2018
37. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells..  Science translational medicine.  10. 2018
38. Novel Latency Reversal Agents for HIV-1 Cure..  Annual review of medicine.  421-436. 2017
39. Lues Maligna..  Open forum infectious diseases.  4:-. 2017
40. Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer..  Open forum infectious diseases.  4:-. 2017
41. Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation..  Cell reports.  18:1324-1334. 2017
42. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo..  Retrovirology.  13:-. 2016
43. HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function..  Frontiers in immunology.  -. 2016
44. HIV-1 Eradication: Early Trials (and Tribulations)..  Trends in molecular medicine.  22:10-27. 2015
45. BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency..  Cell host & microbe.  18:345-53. 2015
46. Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus..  AIDS research and human retroviruses.  32:187-93. 2015
47. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients..  Antimicrobial agents and chemotherapy.  59:5984-91. 2015
48. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  58:883-90. 2013
49. Urinary tract infections: current and emerging management strategies..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  57:719-24. 2013
50. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration..  Proceedings of the National Academy of Sciences of the United States of America.  110:E448-57. 2013
51. Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors..  Journal of virology.  85:10399-403. 2011
52. Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy..  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.  51:195-8. 2011
53. Short communication: dynamic constraints on the second phase compartment of HIV-infected cells..  AIDS research and human retroviruses.  27:759-61. 2011
54. Spinal epidural abscess: current diagnosis and management..  Current infectious disease reports.  12:484-91. 2010
55. Seronegative HIV-1 infection: a review of the literature..  AIDS (London, England).  24:1407-14. 2010
56. Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk..  AIDS (London, England).  24:1603-4; author reply 1604. 2010
57. A case of seronegative HIV-1 infection..  The Journal of infectious diseases.  201:341-5. 2010
58. A perfect storm. Gastric bezoar..  The American journal of medicine.  122:519-21. 2009
59. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy..  Proceedings of the National Academy of Sciences of the United States of America.  106:9403-8. 2009
60. Surgical management of maxillofacial uremic osteodystrophy: a case report..  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.  65:1825-9. 2007